June 3, 2019
A large, randomized immunotherapy clinical trial continues to show improved overall survival and progression-free survival in advanced lung cancer patients, researchers reported at this year’s American Society for Clinical Oncology meeting. The update on the KEYNOTE-189 trial provides nearly two years data on use of the immunotherapy drug pembrolizumab in combination with platinum-based chemotherapy […]
